Modeling of the Placebo Response in Parkinson’s Disease
Objective: The objective of this study was to investigate the predictability of the placebo response in Parkinson's disease (PD) subjects participating in a randomized clinical…Relationship of satisfaction and adherence in remote digital monitoring: Results from a clinical drug trial in early Parkinson’s disease
Objective: To investigate satisfaction with daily remote monitoring with a digital health technology tool (DHTT) in individuals with early Parkinson’s disease (PD) and the relationship…LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials
Objective: To evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of the LRRK2 inhibitor, DNL151 (BIIB122), in healthy volunteers (HVs) and Parkinson’s disease (PD) patients. Background:…A new fully implantable Adaptive Deep Brain Stimulation system tested for the first time in patients with Parkinson’s Disease
Objective: This multicenter double-blind crossover study has been designed to evaluate the safety and efficacy of adaptive Deep Brain Stimulation delivered through an innovative IPG…Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson’s Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT
Objective: The long-term effectiveness of a Deep Brain Stimulation (DBS) device capable of Multiple Independent Current Control (MICC) is assessed in a prospective, sham-controlled, double-blind…Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study
Objective: Our aim was to analyze the effectiveness of safinamide on sleep in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications
Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…The potential of GBA1 knock-out medaka as a model animal in the search for therapeutic compounds for GBA1-related α-synucleinopathy
Objective: This study was performed to search for therapeutic agents for GBA1-related α-synucleinopathy. Background: The GBA1 gene is the causative gene of Gaucher’s disease (GD).…
- 1
- 2
- 3
- …
- 132
- Next Page »